Pure Financial Advisors Inc. grew its holdings in Pfizer Inc. (NYSE:PFE) by 1.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,154 shares of the biopharmaceutical company’s stock after acquiring an additional 400 shares during the period. Pure Financial Advisors Inc.’s holdings in Pfizer were worth $790,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. New England Investment & Retirement Group Inc. bought a new stake in Pfizer in the first quarter worth approximately $26,000. Lion Street Advisors LLC bought a new stake in shares of Pfizer during the 1st quarter worth $27,000. Benjamin Edwards Inc. boosted its holdings in shares of Pfizer by 49.8% during the 1st quarter. Benjamin Edwards Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 335 shares during the period. Disciplined Investments LLC boosted its holdings in shares of Pfizer by 43.3% during the 1st quarter. Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 347 shares during the period. Finally, HighMark Wealth Management LLC bought a new stake in shares of Pfizer during the 4th quarter worth $58,000. 70.28% of the stock is owned by institutional investors.
Several research firms recently issued reports on PFE. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price objective for the company. in a report on Monday, May 4th. Piper Sandler upped their price objective on shares of Pfizer from $18.50 to $24.00 in a report on Friday, June 26th. JPMorgan Chase & Co. decreased their price objective on shares of Pfizer from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Monday, June 1st. Mizuho initiated coverage on shares of Pfizer in a research note on Monday, June 29th. They set a “buy” rating and a $38.00 target price for the company. Finally, Morgan Stanley cut their target price on shares of Pfizer from $43.00 to $36.00 and set an “equal weight” rating for the company in a research note on Thursday, April 2nd. Ten equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $38.72.
Shares of PFE stock traded down $0.40 during mid-day trading on Wednesday, reaching $33.64. The company’s stock had a trading volume of 12,680,076 shares, compared to its average volume of 33,425,040. Pfizer Inc. has a 1-year low of $27.88 and a 1-year high of $44.10. The company has a market cap of $189.03 billion, a P/E ratio of 12.21, a PEG ratio of 2.70 and a beta of 0.68. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.78 and a current ratio of 1.02. The firm’s 50-day moving average is $35.11 and its two-hundred day moving average is $36.13.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.09. Pfizer had a net margin of 31.17% and a return on equity of 25.76%. The company had revenue of $12.03 billion during the quarter, compared to analysts’ expectations of $11.38 billion. During the same quarter in the prior year, the company posted $0.85 EPS. The business’s revenue was down 8.3% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.88 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 31st will be paid a $0.38 dividend. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.52%. The ex-dividend date is Thursday, July 30th. Pfizer’s dividend payout ratio is 51.53%.
In related news, EVP Douglas M. Lankler sold 65,000 shares of the stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $37.85, for a total transaction of $2,460,250.00. Following the completion of the sale, the executive vice president now owns 135,375 shares in the company, valued at approximately $5,123,943.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jennifer B. Damico sold 2,181 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $36.13, for a total transaction of $78,799.53. Following the sale, the senior vice president now owns 7,542 shares of the company’s stock, valued at approximately $272,492.46. The disclosure for this sale can be found here. In the last 90 days, insiders sold 69,362 shares of company stock valued at $2,622,691. Corporate insiders own 0.08% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: What is the Euro STOXX 50 Index?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.